1. Malaysia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
DXN Holdings Bhd

DXN Holdings Bhd

MMYX:DXN
0.47
MYR
+0.01
(+1.09%)
7.94P/E
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
221.59
210.67
249.32
0.32
0.36
0.38
0.38
0.38
Basic EPS, GAAP
48.48
38.43
48.73
0.06
0.06
0.07
0.05
0.06
Free Cash Flow per Basic Share
31.12
22.12
13.81
0.03
0.05
0.06
0.04
0.05
Dividend per Share
11.03
16.05
24.61
0.01
0.02
0.04
0.04
0.04
Book Value per Share
0.14
0.12
0.15
0.19
0.26
0.25
0.27
0.25
Tangible Book Value per Share
0.14
0.12
0.15
0.19
0.26
0.25
0.27
0.25
Basic Weighted Avg Shares
5
5
5
4,985
4,950
4,973
4,972
4,972
Sales/Revenue/Turnover
1,105
1,050
1,243
1,601
1,803
1,908
1,898
1,912
Operating Margin (%)
31.17
27.29
29.29
28.59
26.77
27.35
23.88
26.62
Depreciation Expense
25
31
39
39
56
65
71
65
Net Income, GAAP
242
192
243
275
311
328
272
316
Effective Tax Rate (%)
26.62
30.07
32.37
36.48
32.37
36.06
37.18
36.48
Profit Margin (%)
21.88
18.24
19.55
17.2
17.25
17.19
14.3
16.54
Working Capital
191
140
191
299
436
375
395
360
LT Debt
25
28
47
62
15
24
32
31
Total Equity
711
630
812
1,025
1,358
1,337
1,436
1,322
Return on Invested Capital (%)
- -
21.88
24.11
23.6
22.34
21.3
17.6
20.77
Return on Capital (%)
- -
20.56
24.38
22.43
21.72
21.43
16.74
20.62
Return on Common Equity (%)
- -
30.49
36.21
31.95
27.75
25.85
20.69
25.11

Capital Structure

MYR

•

in mil. unless spec.
Aug'25
Nov'25
May'26
ST Debt
143
141
157
LT Borrowings
- -
- -
- -
LT Finance Leases
18
24
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,973
4,972
4,972
Market Capitalization
3,083
2,412
2,511

Working Capital

MYR

•

in mil. unless spec.
Aug'25
Nov'25
May'26
Total Current Assets
1,137
1,175
1,000
Cash, Cash Equivalents & STI
681
712
556
Accounts Receivable, Net
106
123
130
Inventories
280
282
267
Total Current Liabilities
664
659
640
Payables & Accruals
- -
- -
- -
ST Debt
143
141
157
Deferred Revenue
- -
- -
- -

Growth Rates

MYR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
18.71%
7.38%
Free Cash Flow
- -
25.66%
-39.72%
Net Income, GAAP
- -
8.27%
-17.24%
Sales/Revenue/Turnover
- -
13.02%
-0.52%
Total Cash Common Dividend
- -
31.2%
24.92%

Quarterly Revenue

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
475
488
486
459
1,908
2026
479
- -
463
475
1,898
2027
443
- -
- -
- -
- -

Quarterly Earnings Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.02
0.01
0.02
0.02
0.07
2026
0.01
- -
0.01
0.01
0.05
2027
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.02
0.01
0.01
- -
0.04
2026
0.02
- -
0.01
0.01
0.04
2027
0.01
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Prajith Pavithran
Full Time Employees
3,374
Sector
Health technology
Industry
Pharmaceuticals: other
Address
DXN Cyberville Cyberjaya SE Malaysia 63000
IPO Date
May 19, 2023
Website
dxn2u.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
DXN Holdings Bhd. (5318.KL) is an investment holding company engaged in the cultivation, manufacturing, marketing, and direct selling of health-oriented and wellness consumer products worldwide. The company offers a comprehensive portfolio of core products, including fortified food and beverages such as Ganoderma-based coffee, tea, cordyceps cereals, spirulina cereals, and non-alcoholic drinks; health and dietary supplements featuring Ganoderma (Lingzhi), traditional medicines, and natural foods; personal care and cosmetics encompassing skin care, household products, and water treatment systems; as well as other related items like biodiesel, confectionery, biscuits, and instant coffee. DXN operates through vertically integrated facilities, including seven cultivation sites and 13 manufacturing plants across Malaysia, China, India, Indonesia, Dubai, Mexico, Nepal, and Bangladesh, serving over 20 million registered distributors in more than 180 countries spanning Latin America, Asia, North America, Africa, Europe, the Middle East, and Oceania. Founded in 1993 by Datuk Lim Siow Jin and headquartered in Alor Setar, Malaysia, the company is a subsidiary of LSJ Global Sdn. Bhd. and maintains diversified operations in property development, information technology consulting, agro farming, tourism (including cafes, glamping resorts, and marine sanctuaries), and research in biotechnology and ganotherapy. In recent developments, DXN has pursued aggressive global expansion, investing RM119.2 million in fiscal year 2024 (ended February 2024) for new manufacturing facilities in China, India, Dubai, Mexico, and Peru, with additional plants in Nepal and Bangladesh slated for commercial production by late 2024; the company plans over RM125 million in capital expenditures for 2025 to support entry into markets like Brazil, Argentina, Chile, Zambia, and Ghana. Further strengthening its Middle East presence, a wholly-owned subsidiary acquired a residential apartment in Dubai's Burj Khalifa for AED6.4 million (RM7.4 million) in September 2025 and opened a new member hub in Dubai; these initiatives, alongside robust financials including record FY2025 revenue of RM1.9 billion and net cash positions exceeding borrowings, underscore DXN's focus on production capacity enhancement and high-growth regions.